Candida auris

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 8, 2024
Infection, Congress, Candida glabrata, Investment, Mouse, Data analysis, NIH, Fungal infection, Research, ECCMID, Clinical trial, FURI, GSK, Antimalarial medication, Patient, Candidiasis, CMC, Chemistry, National Institutes of Health, Candida auris, Biotechnology, Mucorales, Pharmaceutical industry

Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.

Key Points: 
  • Phase I-enabling development activities for SCY-247, the second generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to progress.
  • Research and development expense for the quarter ended March 31, 2024 was $7.2 million compared to $6.8 million for the same period in 2023.
  • SG&A expense for the quarter ended March 31, 2024 decreased to $3.7 million from $4.8 million for the same period in 2023.
  • Cash, cash equivalents and investments totaled $94.2 million on March 31, 2024, compared to $98.0 million on December 31, 2023.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, April 9, 2024
Antimalarial medication, Polyene, Fungal infection, Candidiasis, Congress, Biotechnology, Azole, Candida auris, Patient, Mouse, Infection, University, NOS, Echinocandin, University of Texas System, Fluconazole, ECCMID, European, Candida glabrata, Pharmaceutical industry

These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.

Key Points: 
  • These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.
  • Candida auris is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat.
  • The work here utilized the National Institute of Allergy and Infectious Diseases’ (NIAID’s) suite of preclinical services for in vivo testing (Contract Nos.
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Retrieved on: 
Tuesday, February 20, 2024
Infection, Bangladesh Technical Education Board, Fungus, Hospital, Candida auris, NIAID, NIH, Marketing, FDA, Food, Tafenoquine, Risk, Malaria, Patient, Monash University, Oxidative stress, Ageing, Research, Fungal infection, Pharmaceutical industry

C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.

Key Points: 
  • C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients.
  • The study will be conducted by Monash University in Melbourne, Australia, beginning in the second quarter of 2024.
  • “The rapid transmission of Candida auris in healthcare facilities is a very real threat and the need for a safe, effective treatment option is becoming more urgent every day,” said 60 Degrees Pharmaceuticals Chief Executive Officer and President, Geoff Dow.
  • Like other 8-aminoquinoline antimalarials, tafenoquine is expected to kill fungi by disrupting cellular responses to oxidative stress, differentiating it from other antifungals.

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 15, 2024
Human services, International, Candida auris, Sepsis, Acinetobacter baumannii, FDA, Growth, U.S. FDA, CRG, Therapy, Research, Panel

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) --  T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2023.
  • Achieved full year 2023 total revenue of $7.2 million, including sepsis and related product revenue of $6.8 million and research and contribution revenue of $0.4 million.
  • Achieved fourth quarter 2023 total revenue of $1.7 million, comprised entirely of product revenue including record sales of the T2Bacteria Panel in the U.S.
  • Executed contracts for 26 T2Dx® Instruments in 2023, including 19 T2Dx Instruments from outside the U.S. and 7 T2Dx Instruments from the U.S.

Basilea provides portfolio status update

Retrieved on: 
Friday, January 5, 2024
European Commission, Partnership, Yeast, ABSSSI, Fungus, FDA, Antifungal, PDUFA, DXR, WHO, European, Staphylococcus aureus, Genetically modified bacteria, NDA, Bronchopneumonia, SAB, Civil service commission, USD, Infection, Candida auris, Fungal infection, World Health Organization, Biofilm, Patient, Staphylococcus, CABP, Pharmaceutical industry

By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.

Key Points: 
  • By year-end 2023, Cresemba was marketed in more than 70 countries, including the United States (US), most EU member states, China and Japan.
  • In August, Basilea submitted a similar application for a pediatric label extension of Cresemba in the European Union and anticipates a decision by the European Commission around mid-2024.
  • Basilea expects to enter into a commercialization partnership agreement for ceftobiprole in the US prior to the FDA decision.
  • For fosmanogepix, Basilea anticipates to start a phase 3 study in invasive yeast infections mid-2024 and a phase 3 study in invasive mold infections, by year-end 2024.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
NDA, Security (finance), IND, Investment, Risk, GSK plc, Tablet, Biotechnology, Hansoh Pharmaceutical, Mucorales, VVC, Research, Data analysis, Medical Mycology, Antimalarial medication, FDA, FURI, GSK, Candidiasis, NIH, TIMM, Phase, Congress, Candida auris, Cryptocurrency, Pharmaceutical industry, Beauty salon

Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.

Key Points: 
  • Under the agreement, SCYNEXIS has received the $90 million upfront payment as well as the first development milestone of $25 million.
  • SCYNEXIS became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp.
  • Cash, cash equivalents and investments totaled $105.2 million on September 30, 2023, compared to $73.5 million on December 31, 2022.
  • Based upon the company’s current operating plan, SCYNEXIS believes that its existing cash, cash equivalents and investments provides a cash runway beyond two years.

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Retrieved on: 
Monday, November 13, 2023
NDA, Isavuconazonium, Pfizer, Safety, Food, US Foods, Basilea Pharmaceutica, Patient, FDA, Fungal infection, USD, CHF, FY, Candida auris, Pharmaceutical industry, Fungemia, Allschwil

In addition, Basilea has acquired the rights to a preclinical antifungal compound.

Key Points: 
  • In addition, Basilea has acquired the rights to a preclinical antifungal compound.
  • Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action.
  • Basilea assumes all rights and obligations from previous agreements, comprising potential development, regulatory, and commercial milestone payments of up to USD 396 million, as well as tiered single-digit royalty payments.
  • Correspondingly, the BARDA reimbursements, as well as operating expenses, will be reduced by the amount of such application fee.

Molecular Designs releases their new Candida auris PCR Simplicity Panel™

Retrieved on: 
Thursday, November 9, 2023
Simplicity, Research, GMP, Candida auris, Immunodeficiency, Patient, RT-PCR, Molecular design software, PCR, ISO, Laboratory, Workflow, Infection, Health care, Hospital, Vaccine, Candida

BIRMINGHAM, Ala., Nov. 9, 2023 /PRNewswire/ -- Molecular Designs, a leading provider of molecular infectious disease assays, has released its latest product, the Candida auris Simplicity Panel™.

Key Points: 
  • BIRMINGHAM, Ala., Nov. 9, 2023 /PRNewswire/ -- Molecular Designs, a leading provider of molecular infectious disease assays, has released its latest product, the Candida auris Simplicity Panel™.
  • It aims to improve the workflow for clinical and research laboratories with the advances they've achieved with their Simplicity Panel ™ technology.
  • The Candida auris Simplicity Panel™ is an in-vitro multiplex real-time polymerase chain reaction (RT-PCR) assay for qualitatively identifying this fungal pathogen.
  • In so doing, Molecular Designs aims to help laboratories respond to the challenge posed by Candida auris.

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Retrieved on: 
Tuesday, October 24, 2023
Yeast, TIMM, European Confederation, IV, Antimalarial medication, Auris, Candida albicans, Biotechnology, Congress, Professor, ECMM, Mouse, Candida auris, University of Graz, University, Medical Mycology, Fungal infection, Patient, Associate, Mycology, Pharmaceutical industry

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.

Key Points: 
  • JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens.
  • “We are excited to see the progress in the development of this novel compound from the fungerp family,” said Dr. Martin Hoenigl, FECMM, Associate Professor of Translational Mycology at University of Graz, Austria and president of the European Confederation of Medical Mycology (ECMM).
  • Results illustrated the potent and broad-spectrum in vitro activity of SCY-247, including against a large array of yeasts, molds and dimorphic fungi.
  • Results also demonstrated SCY-247’s extensive tissue distribution in mice, including brain penetration.

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

Retrieved on: 
Wednesday, October 11, 2023
Antifungal, Fluconazole, Bloodstream infections, Candida auris, Taurolidine, Pharmaceutical industry

The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.

Key Points: 
  • The abstract being presented highlights data regarding in vitro activity of taurolidine against the fungus Candida auris, an emerging cause of life-threatening bloodstream infections, with increasing resistance to common antifungal agents.
  • Taurolidine exhibited in vitro antimicrobial activity against all C. auris strains and isolates regardless of geographic source, year of isolation, or clade.
  • There was no evidence that taurolidine activity was affected by resistance to amphotericin B or fluconazole.
  • The abstract is available through the IDWeek conference website.